Sana Biotechnology
SANA
119 hedge funds and large institutions have $507M invested in Sana Biotechnology in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 32 reducing their positions, and 17 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.19% less ownership
Funds ownership: 67.45% → 67.26% (-0.19%)
5% less funds holding
Funds holding: 125 → 119 (-6)
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
34% less capital invested
Capital invested by funds: $770M → $507M (-$263M)
70% less call options, than puts
Call options by funds: $8K | Put options by funds: $27K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.03M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.05M |
| 3 |
Goldman Sachs
New York
|
+$2.22M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$1.4M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$3.19M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.07M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$2.9M |
| 4 |
Millennium Management
New York
|
-$1.86M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$1.8M |
SANA Hedge Fund Activity: Q4 2022 in Review
119 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q4 2022, worth a combined $507M — down 34% from $770M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SANA and 13 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 40 added.
The largest buyer was BlackRock, adding an estimated $4.03M. The largest seller was Renaissance Technologies, cutting an estimated $3.19M.
- 119 institutional investors held Sana Biotechnology (SANA) as of Q4 2022, down from 125 in Q3 2022.
- Funds reported $507M of Sana Biotechnology stock for Q4 2022, down 34% quarter-over-quarter.
- 13 funds opened new Sana Biotechnology positions in Q4 2022 and 17 closed out, a net change of -4 holders.
- The largest Sana Biotechnology buyer in Q4 2022 was BlackRock, an estimated $4.03M added.
- The largest Sana Biotechnology seller in Q4 2022 was Renaissance Technologies, an estimated $3.19M sold.
Based on aggregated 13F filings for Q4 2022.